Evidence map›Paper›PMID 41967639›Full record

ArticleThe Journal of biological chemistry2026

Meeting report on FASEB protein arginine methylation: mechanism to therapeutics.

David Shechter, Rong Huang, Pooja Shah, Thierry Dubois, Xiao-Meng Li, Andrey Parhitko, Mark T Bedford, Shihuan Kuang, Taiping Chen, Yanzhong Yang and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of biological chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

David ShechterDepartment of Biochemistry, Albert Einstein College of Medicine, Bronx, New York, USA. Electronic address: david.shechter@einsteinmed.edu.
Rong HuangBorch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, Indiana, USA.
Pooja ShahDepartment of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Thierry DuboisInstitut Curie, PSL University, Sorbonne University, Translational Research Department & CNRS UMR144, Paris, France.
Xiao-Meng LiThe Hong Kong University of Science and Technology (Guangzhou), Guangzhou, China.
Andrey ParhitkoAging Institute, UPMC and University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Mark T BedfordDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Shihuan KuangDuke University School of Medicine, Durham, North Carolina, USA.
Taiping ChenDepartment of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Yanzhong YangDepartment of Cancer Genetics and Epigenetics, Beckman Research Institute, City of Hope Cancer Center, Duarte, California, USA.
Purusharth RajyaguruIndian Institute of Science, Bengaluru, Karnataka, India.
Dalia Barsyte-LovejoyDepartment of Pharmacology and Toxicology, University of Toronto and Structural Genomics Consortium, University Health Network, Toronto, ON, Canada.
Xinyang ZhaoDepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.
Wei XuMcArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Clare C DaviesDepartment of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK.
Irina TikhanovichDepartment of Internal Medicine and Liver Center, University of Kansas Medical Center, Kansas City, Kansas, USA.
Ngoc Tung TranHerman B Wells Center for Pediatric Research, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Koichiro KakoLife Science Center for Survival Dynamics, Tsukuba Advanced Research Alliance (TARA), University of Tsukuba, Tsukuba, Japan.
Misuzu HashimotoLaboratory of Biological Chemistry, Faculty of Applied Biological Sciences, Gifu University, Gifu, Japan.
Minkui LuoChemical Biology Program, Memorial Sloan Kettering Cancer Cente, New York, USA; Department of Pharmacology, Weill Cornell Medical College, Cornell University, New York, New York, USA.
Joan M HevelDepartment of Chemistry and Biochemistry, Utah State University, Logan, Utah, USA.
Akiyoshi FukamizuLife Science Center for Survival Dynamics, Tsukuba Advanced Research Alliance (TARA), University of Tsukuba, Tsukuba, Japan.
Michael C YuDepartment of Biological Sciences, University at Buffalo, Buffalo, New York, USA. Electronic address: mcyu@buffalo.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The inaugural FASEB conference Protein Arginine Methylation: Mechanism to Therapeutics was held in Tsukuba, Japan (January 5-8, 2026), and brought together investigators studying protein arginine methyltransferases (PRMTs) and its methylarginine product. Post-translational arginine methylation, found as monomethylarginine (MMA/Rme1), asymmetric dimethylarginine (ADMA/Rme2a), and symmetric dimethylarginine (SDMA/Rme2s), is increasingly recognized as a central regulator of RNA metabolism, chromatin function, and cellular stress responses. Presentations highlighted emerging directions for the field, including mechanisms linking PRMT activity to RNA processing and gene expression, roles in genome stability, identification of new methylarginine reader proteins, and connections between PRMT function and cellular metabolism. Work on immune and antiviral pathways and neuroscience further expanded the biological scope of PRMT activity. At the same time, significant advances in chemical probes, degraders, and selective inhibitors are enabling more precise interrogation of PRMT biology and accelerating efforts to translate these discoveries into therapeutic strategies.

Indexed as

ArginineProtein-Arginine N-MethyltransferasesAnimalsHumansMethylationProtein Processing, Post-TranslationalArginineProtein-Arginine N-Methyltransferasescancer therapeuticschemical probesgenome stabilitymethylargininemethylarginine reader proteinsPRMTsprotein arginine methylationRNA processing

Identifiers

PMID41967639
PMCPMC13208669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.